Aileron Therapeutics files for a $69M IPO as new offerings heat up

Joseph Yanchik, Aerilon

Aileron Therapeutics has set out to raise $69 million in the latest biotech IPO to hit the street.

Their lead drug — ALRN-6924 — is focused on p53, a familiar and very frustrating target in the cancer R&D world. Still in early studies, Aileron has gathered a collection of initial patient responses to the drug, which targets MDMX and MDM2.

Aileron has had a low profile for the last few years. It’s jumping into the IPO queue now after a growing lineup of drug developers have sought investors’ embrace, with varying but generally positive results.

The biggest shareholder in the Cambridge, MA-based biotech is Apple Tree Partners, with 22.4% of the stock. Novartis BioVentures comes in a close second with 21%. CEO Joseph Yanchik, meanwhile, has a 4% stake.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->